Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision

The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September.